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Summary.-The humoral and cellular components of the antibody-dependent
cellular cytotoxicity (ADCC) against allogeneic human colonic tumour cell lines were
evaluated. The2 colon cell lines used in this study (HT-29 and ACC-20) were found
byimmunofluorescence to have carcinoembryonic antigen (CEA) ontheirsurface, and
to become sensitive to the lytic effect of unstimulated lymphocytes after coating with
heterologous anti-CEA. This reaction was used to evaluate the ADCC activity of
mononuclear cells from the peripheral blood of patients with gastrointestinal cancer
(mostly local extensive colo-rectal). Remarkable variability was found in the lytic
capability (2-50% specific lysis) of both cancer and non-cancer mononuclear cells,
with no significant difference between them. Sera from 127 cancer patients and 91
non-cancer patients were tested, using the reaction with heterologous anti-CEA as
positive control and as a reference point. In 46 cases (21%) the sera were reactive in
this system, and 43 of them were of Blood Group 0. However, there was no difference
between the cancer patients and the normal controls. The antigenic determinant
involved in this reaction is not the Blood Group A specificity but, most probably, a
polypeptide common to CEA and A (as shown in the following publication). In
addition, trials for the elimination of the non-tumour-specific reaction, by absorption
or inhibition, failed to disclose a tumour-specific one. The value of the ADCC assay in
monitoring human tumour immunity, and possible ways of eliminating reactivity to
normal antigens in this system, are discussed in the light of these findings.
ANTIBODY-DEPENDENT cellular cyto-
toxicity (ADCC) is a well defined in vitro
reaction (Lovchik & Hong, 1977; Perlman,
1976) of unknown biological significance.
The specificity of the reaction is deter-
mined by the antibodies that coat the
target cells. The nonspecific cellular effec-
tor component is the K lymphocyte
(Perlman, 1976) or sometimes the macro-
phage (Kohl et al., 1977) or polymorpho-
nuclear leucocyte (Gale & Zighelboim,
1975). All ofthem recognize the Fc portion
of the coating antibody.
This reaction has been implicated in
various in vivo immune processes, includ-
ing those against tumours (Lamon et al.,
1976), virus-infected cells (Pearson & Orr,
1976), transplants (Jeannet & Vassalli,
1976) and autoimmunity (Feldman et al.,
1976). However, although there is some
evidence that ADCC does occur in these
conditions, it has been impossible so far to
demonstrate directly their relative im-
portance among the multitude of immune
reactions taking place in vivo. As far as
tumour immunity is concerned, serum and
lymphocyte cooperation was demonstrated
in vitro in mice bearing Moloney sarcoma
virus-induced or 3-methylcholanthrene-
induced sarcomas and mammary-tumour
virus-induced adenocarcinoma (Pollack
et al., 1972), as well as in rats with Gross
virus-induced lymphoma (Ortiz de Lan-
dazuri et al., 1974). Successful inhibition of
murine neuroblastoma by ADCC was
demonstrated in a modified Winn's test
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(Byfield et al., 1976). With human tumours
the condition is much less clear, and there
are few publications suggesting that
specific ADCC might occur in a limited
number of cases (Kodera & Bean, 1975;
Hellstrom et al., 1973; Hersey et al., 1973;
Hakala & Lange, 1974). However, the
remarkable sensitivity of this reaction to
low antibody levels (Zighelboim et al.,
1973; Perlman, 1976) justify further
evaluation of its applicability to the
monitoring of antitumour activity in
humans.
The present study was undertaken in
order to use the ADCC reaction in the
human colonic-tumour system using serum
orlymphocytes from patients and matched
controls against human colonic tumour
cell lines. Our observations, and those of
others (Von Kleist et al., 1975), suggest
that carcinoembryonic antigen (CEA) and
other surface antigens are present un-
changed on these cells, despite their long
period in vitro. In addition, their morpho-
logy in culture and histology as tumours
in nude mice suggest that their tumour
characteristics are well preserved. Pre-
liminary distinct ADCC reactions with
both heterologous anti-CEA and some
patients' sera encouraged further study in
this direction.
MATERIALS AND METHODS
Cells and cell cultures.-The cell lines used
in these experiments originated from adeno-
carcinoma of the colon (HT-29, ACC-20),
malignant melanoma (SK-mel, IgR3, 8342,
8322) and adenocareinoma of the endo-
metrium (Endo 1-11 and Endo-2). ACC-20 is
a cell line developed in our laboratory fronm
malignant effusion ofa patient with cancer of
the colon. The other cell lines were kindly
given to us by Dr Brunner (SK-mel and
IgR3) and Dr Sordat (HT-29 and the endo-
metrial lines), both of the Swiss Institute for
Experimental Cancer Research, Lausanne,
and Dr G. Moore (8342, 8322), Denver
General Hospital, Denver, Colorado, U.S.
Only colonic-tumour cells were positive for
cell-surface immunofluorescence with anti-
CEA serum. Cells were cultured in plastic
flasks (Falcon) in Dulbecco's modified Eagle's
medium, high glucose (GIBCO) with 10%
foetal calf serum (GIBCO). Routine passage
ofcells in a monolayer (HT-29, ACC-20, IgR3,
8342, 8322) was made once a week with 0 25%
trypsin solution (1: 300) or by dilution for
cells in suspension (SK-mel and endometrial
lines). There was no detectable bacterial,
fungal or mycoplasmal contamination of
cultures used in these studies.
Sera.-Goat anti-CEA serum, lyophilized
globulin fraction (ammonium sulphate pre-
cipitation) was kindly given to us by Dr Gold
from McGill University, Montreal, Canada.
This antiserum was dialysed and absorbed on
a mixture of normal human lung, liver and
colonic tissues and normal human serum.
Normal goat serum (NGS) was used as a con-
trol. 218 samples of human sera were col-
lected. Of those, 127 were from cancer
patients (61 with local extensive colo-rectal
cancer, 15 with gastric and 12 with pan-
creatic cancers, 23 with melanoma Stage I or
II and 16 with other tumours). 91 sera were
from people without cancer (38 of them
healthy young donors and 53 controls
matched for age, sex and also, if possible,
disease states such as atherosclerotic cardio-
vascular disease, hypertension or diabetes
mellitus).
Mononuclear cells.-Blood samples were
drawn into heparinized syringes and allowed
to settle for 30-45 min. The leucocyte-rich
plasma was separated and layered on Ficoll-
Hypaque solution for density separation of
lymphocytes (Thorsby & Bratlie, 1970). Cells
at interface were aspirated and washed x 3
in serum-free medium. These preparations
contained 92-97% mononuclear cells, most of
them (70-85%) with the morphological
appearance of small lymphocytes. Such cell
samples contained 54-7 + 10-2% and 50 7 +
117% E rosettes in normal adults and cancer
patients respectively (Shoham et al., to be
published), and 5-10% B rosettes (with mouse
red blood cells). The "null" cell population
was not further analysed for the presence of
non-lymphocyte white blood cells (Zucker-
Franklin, 1974; Currie et al., 1978). Neverthe-
less, we will refer conventionally to these
mononuclear cell preparations as peripheral-
blood lymphocytes (PBL) with the under-
standing that other white blood cells present
in these preparations may contribute to the
ADCC reaction (Kohl et al., 1977; Gale &
Zighelboim, 1975). Viability was tested by
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eosin-Y exclusion, 95-100% ofthe cells being
viable.
Assay of ADCC.-Target cells (from the
above-mentioned cell lines) were harveste(d
and incubated with 200 ,tCi 51Cr for 90 min at
37°C, washed x 2, incubated uvvith goat anti-
CEA, normal goat serum or human test
serum, for 30 min at 37°C, then washed x 2.
100 ,ul of the target cells (105/ml) were mixed
with 100 ,ul of mononuclear cells (107/ml) or
with medium and incubated for 18 h. Then
200 1l medium was added to each tube,
which was vortexed and centrifuged. 200 pi of
the supernatant was transferred to another
tube, and the results read in a Packard Auto-
Gamma Spectrometer. The results were cal-
culated according to the following formula:
0 chromium release= A-x100 A+Ax10
Where A is the original tube (cell pellet+200
,ul residual supernatant) and A is the tube
wNith the 200 ,ul transferred supernatant.
Maximal release was determined on freeze-
thawed cells and was found to be very close to
the total count; 00 specific lysis = 00 experi-
mental release- 0 spontaneous release.
RESULTS
Basicfeatures of the assay system
Antibody-dependent cellular cytotox-
icity to human colonic-tumour cells
(HT-29) was demonstrated by incubating
these cells with anti-CEA and then with
PBL. The cytotoxicity was measured by
51Cr release. Table I contains crude data
which reveal several features of the assay
system. The maximum releasable 51Cr
approaches very closely to the total counts
per sample. As the latter value is available
for each point in our assay, it was found
more accurate to calculate 00 specific lysis
from it rather than from the maximum
release. The spontaneous release does not
exceed 30%o in HT-29 and the other cell
lines chosen for assay.
Cellular cytotoxicity against uncoated
cells (cell-mediated cytotoxicity, CMC) is
low, and approaches the spontaneous re-
lease (Tables I and II). This is the case
with most of the PBL samples tested, but
not with all (Fig. 3). Similar results in both
ADCC and CMC reactions were obtained
with a second colonic tumour-cell line
(ACC-20).
The ADCC reaction with anti-CEA is
apparently immunologicallyspecific (Table
II). Normal goat serum (NGS) as well as 2
antisera to unrelated antigens were in-
active in this system. Coating ofmelanoma
cells and of endometrial tumour cells with
anti-CEA did not change the effect exerted
by lymphocytes per se. Table II represents
TABLE I. Crude data of the assay system
ct/min
Incubation
condlitions* Tube A
AMaximal release 1608
1692
1749
AMedlium onlyt 2523
(spontaneous 2480
release) 2537
With PBL+ (CAIC) 2948
2869
2832
With anti-CEA then 2:384
PBL (ADCC) 2277
2324
Tube A
1531
1549
1613
360
422
403
537
496
542
723
714
680
Total
count
3139
3241
3362
2883
2902
2940
3385
3365
3379
.3107
2991
3004
Total
release
3062
3098
3226
720
844
806
1074
992
1094
1446
1428
1360
% 51CI release
Mean + s.d.
97.5
95-6
96 0
25-0
29-1
27-4
31 7
29 5
32-4
46-5
47-7
45-3
96'4 + 0-8
27-1 + 1-7
31-2+1 2
46-5 + 1-0
* HT-29 cells weie labelled with 51Cr and theni stubjected to either freeze-
thawing (maximal release) orincubationi with medlium alone for 18 h (spontaneous
release) with PBL with (ADCC) or without (CMC) preincubation with anti-CEA.
t Similar restults with NGS or anti-CEA-coated cells without added lympho-
cytes.
I Similar iesults with oIr without preincuibation with NGS.
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o% vC release +s.d.
Medillu§ 1PB1
273 ±+ 1*7 4650-94'8
30-5 I6 3:237 + 02
292±+ (9 :31*2+ 1 2
18 8+1 8 29-53+11
209± +0(4 :31 7 + 07
182 + 11 26 8 + 1 6
* (Conulitioiis as in Table I.
t ACC-20 gave similar results.
I Two other mnelainomna cell lines and( 2 endlo-
inetrial cell lines also exhibitedt the samen lytic effect
with or writhout coatiig wvith anti-CEA.
§ Spontaneous release.
LOGIo DILUTION
LTtr. 1. litat)ii of the ADCC activity of
goat anti-CEA. 104 51Cr-labelled H1-29
cells wvere coate(l with reconstituted pi'e-
paration of anti-CEA (8 mg protein/mIl=
log 1) oIn serial loglo (liluitions of it
( O -O) (or with inor mal goat sertum
NXGS and then with 10(i lympho-
cyte.s.
the resuilts witlh otne of the mnelanioma cell
lines as a control.
I)ose-effect relationships
The lytic effect in this assay is (lose-
related both to the sertum concentration
and to the amounit of lymphocytes. Using
I 0-fold (lilutions of the anti-CEA serum
(originally reconstituted to 8 mg/ml pro-
tein) with constant lymphocyte: target
ratio (100:1 writh 104 target cells) we
obtained an approximatelv linear decrease
in the percentage lysis (Fig. 1). The lytic
effect wvas detectable ul) to a I 000-fold
-n
CL)
LYMPHOCYTE/TARGET RATIO
Ficn. 2.-ADCC reaction as a funiction of
lymphocyte/target ratio. 104 HT-29 cells
were inctubated with 1 mg/ml anti CEA
(0 O) or NGS ( O---- C1), then wvvith
vairyinig amouints of PBL (105-106).
diluition. In further experiments we used
anti-CEA in a concentration of 1 mg/ml
protein.
The lymphocyte-dose-dependency ofthe
reaction is shown in Fig. 2. There was a
sharp decline in lysis when the number
of lymphocytes was changed from 106 to
5 x 105 lymphocytes. The following experi-
menits were carried out with 106 PBL.
Patient lymphocytes as the tested variable
PBL from 41 healthy subjects or non-
cancer patients and 25 with gastrointes-
tinal (CI) cancer were tested in this assay
for both ADCC against anti-CEA-coated
HT-29 cells and CMC against uncoated
cells (Fig. 3). Most of the patients (21 /25)
had local extensive large-bowel tumour
without metastasis, and did not receive
chemotherapy or radiotherapy at the test
time. The score in Fig. 3 reflects the fact
that the ability of PBL to participate in
ADCC flulctuates from the barely measur-
able to about 60%o specific lysis. However,
T'ABLE 11. Sertam, acnd cell controlsfor
spec~Jicity*
.1 re -
Tr,'I,l.g(et inceuibate(d
ce?lls w-ith
;H'T-29t anti-CEA
PBS
SIK-nicI anti-CEA
N(XS
PBS
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FIG. 3. ADCC and CMC activity of PBL from people without cancer and patients with gastro-
intestinal (GI) cancer, mostly (21/25) local extensive colo-rectal adlenocarcinoma before radiation
or chemotherapy. In the non-cancer group the activity of the indiviclual samples was compared to
that of pools from 2 donors.
in most of the cases the reaction was the samples respectively. Only 6/41 and
clearly demonstrated (10O% or more specific 5/27 had 1000 or more specific lysis.
lysis in 33/41 non-cancer and 23/25 cancer Statistical analysis by Wilcoxon's test
patients). In contrast, with uncoated indicates that thereis no difference in both
target cells there was no measurable ADCC and CMC between the non-cancer
lymphocytotoxicity in 27/41 and 16/27 of and cancer group.
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Patient sera as the tested variiable
HT-29 cells were incubated with humnclal
sera taken from non-cancer or cancer
patients, and then with PBL. Anti-CEA-
coated [IT-29 cells served as a positive
control. Here also we obtained a spectrum
of activities from zero (equial to spon-
taneous release) to those approaching
maximal release. However, the variability
introduced by the lymphocytes (Fig. 3)
precludes comparison ofresults with differ-
ent lymphocyte preparation.
Pooling lymphocytes (usually from 2
donors) enabled us to conmpare larger
numbers of serat under uniform conditions
without significantly changing the ADCC
reactivity (Fig. 3) and this served as a
partial answer to this problem. It has to
be mentioned, however, that CMC' of
pooled PBL against uncoated HT-29 cells
was significantly higher (P < 0 01) tha,n
that of unpooled PBL. Moreover, anti-
CEA wAas used as a reference serum for
each PBL sample, and the results with the
patients' sera were related to those ofanti-
CEA by dividing the ° specific lysis (SL)
of each one of the tested sera by that of
anti-CEA. The results were regarded as
the "cytotoxicity index" (CI). The CI of
anti-CEA was, therefore, always I O(
(Table III).
The CI introduced a remarkable unifor-
mity to the results of each serunm tested
witlh several PBL specimenis, or eveni in
different experiments.
Sera from 218 sutbjects Awere t,ested (91
healt,hv individuals or non-cancer patients
and 127 with cancer of various origins). It
was founled in repeated experiments that a
CI < 0 7 is iinsignificant, as compared to
the background, and therefore a CI of 0-7
was t,aken as the boundary between posi-
tive and negative reactions. By this
definition 46/218 (21 %) of the sera were
positive, of which 19/91] (21oo) were from
the non-cancer group and 26/127 (20 4%)
in the cancer grouip. The difference is
obviously insignificant.
XVhen the results were correlated with
the blood group of these subjects (Fig. 4),
it emerged that almost all the reactors
(43/46) were of Blood (roup 0. However,
only 43/83 (5lo%) of the Blood G;roup 0
sera reacted. Blood Group A sera did not
react at all, whereas 2 sera ofBlood Group
B andl I of Group AB also reacted. The
results with Blood Group 0 sera were
further analysed by the Mann-Whitney
U test, as a continuous score wAitfhout re-
garding the 0-7 index cut. This anialysis
also confirmed the absence of difference
between cancer and non-cancer patients.
Moreover, when thle results of Blood-
GrIoup ( cancer sera were scored separ-
ately according to the primary tumour, no
difference among them could be demon-
TABLE III. Conversion of 0% specific lysis (SL) to cytotoxicity index (CI) using the
response with goat anti-CEA as a reference value
Serutimt
aiti-CEA S-8 X -2-2 S-78
[)BSL* -__
Exp). sample S, C.11 SL C( SL CI SL CI
I A 45-7 1 .0 36-2 0(79 40() 0588 NJ)
BS 8 4 1.0 7,2 0-86 7 8 0-93 ND
CX :s34 5 1*0 29-5 0X8.5 2'7 1 (-78 1158 0-:34
I) 22-1 1.0 24 6 1-13 183: 0-82 ND
2 E 18 9 1) 0 16.3 0-86 ND 510l26
F' 274 1 .0 25 1 092 ND ND
3 C 12-5 1t0 ND ND 4 7 036
* Seveni PBL samples w'Oere use(d in 3 experlinents for- the ADCC assay; ainti-
CEA w-as incluide(d in all the experiments and the restults with it are uisedl as
reference CI (1-0). The results with the htumain seria ar-e irelated to it. S-8 ancl S-22
are 2 serulm samples taken from the same patienrt on 2 diffeient occasions an(d ale
positive (CI> 0-7, see text) and 8-78 is fiom aniother patient and(i nlegative
(CI< 0-7).
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Fia. 5. Activity of sera from cancer patients
with different tumours, an(1 Blood Group 0,
expressed as cytoxicity index.
strated (Fig. 5). The single positive Group
AB serum was from multiparous women,
and was found to contain HLA antibodies.
The titre of the positive human sera
was lower than that of anti-CEA, and
approached background activity with
dilutions of -A- or --l- (Fig. 6), without a
difference between cancer and non-cancer
sera, even when initially highly ADCC-
active sera were selected.
DISCUSSION
The 2 components of the ADCC
(cellular and humoral) were tested for
their usefulness in the monitoring of
human tumour immunity in allogeneic
combination with colonic tumour cell
lines.
As far as the cellular aspect is concerned,
there is remarkable variability in the
ability of mononuclear cells of different
subjects to participate in the ADCC
reaction. Such variability has also been
found in other studies (Lovehik & Hong,
1977; Korithavongs etal., 1974). However,
the cells of healthy people and GI cancer
patients do not differ in this characteristic
in our system, which tests mostly patients
with local extensive colo-rectal cancer.
* 00
_ 0 >
* 0
0S S
_ 0 50
* 0 0~~~~~~~~~~~~~~~~~~~~~~0
* S *i . t:~~~~:
S
O" - : .
*
: X
t~~ ~ ~~~~ ~~ E :0 . * a
n)
-240
I
I
-
-
r241 ADCC TO HUMAN COLONIC TUMOUR CELLS. I
1.50
x
w
z
0
0
X
1.00
0.50
1/2 1/4 1'8 1/16 1/32 I/64
SERUM DILUTION
FIGURE 6i. Titration of ADCC activity of huimani positive sera of 3 healthy pleisoiS (A A) or
3 canceir patienits ( *). The patienit sera were selected for high initial cytotoxicity. The
(lashed horizontal lines represent the results with anti-CEA ((definedl as CI = 1 0) ain(l NGS, repre-
senting background lysis.
Other patients with more aclvanced
(lisease also showed the same pattern of'
distribution (data Inot shown). There is no
agreement among other workers regarding
this activity in cancer patients. The works
of Lovehik & Hong (1977), Elhilali et al.
(1976) and Peter et al. (1975a) support, our'
observations, wrhereas Ting & Terasaki
(1974) found (lepressed ADCC-effector
activity in cancer patients. It, has to be
emphasized that the Ficolle-Hypaque-
separated mononuclear cell preparations
may contain substantial numbers of
macrophages (Zucker-Franklin, 1974) and
chloroacetate-esterase-positive cells and
that the percentage of the last-mentionied
cells may be especially high in cancer
patients (Currie et al., 1978). Although
such cells may participate in ADCC (Kohl
et al., 1977; GXale & Zighelboim, 1975)
along with K lymphocytes, quantitative
and kinetic differences in this activity may
exist among them. Taking all these data
together, and in view of the remarkable
variability in this activity in both healthy
persons and cancer patients, we do not feel
that testing for lymphocyte activity in
ADCC has a place in monitoring the
immuLne status of cancer patients.
Twenty-one per cent of the sera tested
\ \ anti CEA
S~~~~~G
A~~~~~~~~~~~~~~ .mNws.~~
0
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were found to be reactive in this system,
and to cause colonic tumour cell lysis to
about the same degree as heterologous
anti-CEA does with undiluted serum. The
titre of the heterologous anti-CEA was
about 20-fold higher than that of the
positive allogeneic sera. However, once
again no difference was found between
cancer patients and normal controls.
Further analysis revealed that almost all
the positive sera (43/46) were of Blood-
Group 0 persons, with 2 of Group B, I of
G(roup AB and none ofGroup A. However,
not all 0-type sera were reactive. Thus,
the reaction was apparently against A
antigen or A-like determinant on the CEA
molecule, which may or may not mask a
more specific reaction towards other
determinants on the CEA molecule or
other colonic-tumour associated antigens.
These possibilities are further analysed in
the following publication (Shoham &
Cohen, 1979), which brings evidence that
the reaction observed is to an antigenic
determinant common to CEA and A, and
maybe normal colon antigen too. This
determinant most probably resides in the
protein portion of the molecule. The in-
hibition of this common activity did not
expose tumour-specific activity.
Lymphocyte dependent antibody (LDA)
activity was looked for in other
human tumour-cell systems. Hellstrom et
al. (1973) showed increased lymphocyte-
mediated tumour-cell destruction in their
test systems with allogeneic combination
of sera from 7 cancer patients (with
different tumours) out of a "much larger
patient material" (unspecified) with no
reference to normal antigens. The same
reservation applies to the work of Hakala
& Lange (1974), who found LDA activity
in 2/40transitional-cell carcinomapatients.
In other publications a large panel of
allogeneic target-tumour cells of the same
histological type was used in order to solve
the problem of immune specificity.
Ferrone & Pellegrino (1977) used several
melanoma cell lines in a complement-
dependent microcytotoxicity assay. They
failed to find melanoma-specific activity as
compared to serum activity in other
cancer patients or correlation to disease
stage. Hersey et al. (1973) found LDA in
sera from AML patients to a panel of allo-
geneic AML myeloblasts, which they felt
may be directed to a leukaemia-associated
antigen. However, some of these patients
had received immunotherapy with allo-
geneic cells, and all of them had been
given multiple transfusions. Thus it is
more plausible that the observed activity
was related to HLA antigens. This notion
is further supported by the recent work of
Gale & MacLennan (1977). Autochthonous
combinations may avoid this confusion.
Kodera & Bean (1975) used such com-
binations and found LDA activity in 4/16
patients, which was apparently related to
disease state. A similar study by Peter et
al. (1975b) in a smaller group of patients
failed to show such activity. However, the
numbers in the last 2 studies are too
small to warrant anyfirm conclusion on the
significance of this activity, and the
difficulties encountered in using autoch-
thonous combinations preclude their large-
scale use. An alternative approach is to
eliminate the activity to HLA and blood-
group antigens by selective absorption or
by inhibition with Fab fragments of
appropriate polyspecific serum. The
potential ofthis approach is demonstrated
in the following publication (Shoham &
Cohen, 1979). However, in the particular
case of colonic tumour cells it failed to
expose any specific tumour activity.
This work was supported in part by research grants
6/74 and 3/7;5 fIom the Israel Cancer Association.
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